IN2012DN03448A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03448A
IN2012DN03448A IN3448DEN2012A IN2012DN03448A IN 2012DN03448 A IN2012DN03448 A IN 2012DN03448A IN 3448DEN2012 A IN3448DEN2012 A IN 3448DEN2012A IN 2012DN03448 A IN2012DN03448 A IN 2012DN03448A
Authority
IN
India
Prior art keywords
compounds
methods
administration
preparing
disclosed
Prior art date
Application number
Other languages
English (en)
Inventor
Hallock Ebetino Frank
Wieslaw Mazur Adam
Lee Martin Dobson Roy
Original Assignee
Warner Chilcott Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Chilcott Co Llc filed Critical Warner Chilcott Co Llc
Publication of IN2012DN03448A publication Critical patent/IN2012DN03448A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574Esters of oxyacids of phosphorus
    • C07F9/65746Esters of oxyacids of phosphorus the molecule containing more than one cyclic phosphorus atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657163Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
    • C07F9/657181Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN3448DEN2012 2009-10-26 2010-10-26 IN2012DN03448A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25488609P 2009-10-26 2009-10-26
PCT/US2010/054124 WO2011056589A1 (en) 2009-10-26 2010-10-26 Bisphosphonate compounds for treating bone metabolism disorders

Publications (1)

Publication Number Publication Date
IN2012DN03448A true IN2012DN03448A (de) 2015-10-23

Family

ID=43478185

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3448DEN2012 IN2012DN03448A (de) 2009-10-26 2010-10-26

Country Status (10)

Country Link
US (3) US8314081B2 (de)
EP (1) EP2493905B1 (de)
JP (1) JP5850842B2 (de)
CN (1) CN102630227B (de)
CA (1) CA2778015C (de)
IL (1) IL219235A (de)
IN (1) IN2012DN03448A (de)
MX (1) MX2012004769A (de)
SG (1) SG10201406846XA (de)
WO (1) WO2011056589A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DN03448A (de) 2009-10-26 2015-10-23 Warner Chilcott Co Llc
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
EA201491335A1 (ru) * 2012-01-06 2015-04-30 Элселикс Терапьютикс, Инк. Бигуанидные композиции и способы лечения метаболических расстройств
AU2015217221A1 (en) 2014-02-13 2016-08-11 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
WO2016003812A1 (en) * 2014-07-02 2016-01-07 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
AU2019207625A1 (en) 2018-01-09 2020-07-30 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2043072B (en) 1979-02-13 1983-11-23 Symphar Sa Diphosphonate compounds
DE3640938A1 (de) 1986-11-29 1988-06-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel
US4990503A (en) 1988-08-12 1991-02-05 Yamanouchi Pharmaceutical Co., Ltd. Heterocyclic bisphosphonic acid derivatives
JPH0699457B2 (ja) * 1988-08-12 1994-12-07 山之内製薬株式会社 ヘテロ環ビスフォスフォン酸誘導体およびその医薬
US5039699A (en) * 1989-03-27 1991-08-13 Lederle (Japan), Ltd. Anti-peptic ulcer agent
US5227506A (en) 1989-09-06 1993-07-13 Merck & Co., Inc. Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors
FI89366C (fi) 1990-12-20 1993-09-27 Leiras Oy Foerfarande foer framstaellning av nya farmakologiskt anvaendbara metylenbisfosfonsyraderivat
US5157027A (en) 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
AU657554B2 (en) * 1991-06-19 1995-03-16 Pharmacia & Upjohn Company Dialkyl (dialkoxyphosphinyl)methyl phosphates as anti-inflammatory agents
JPH05239075A (ja) * 1991-08-27 1993-09-17 Eisai Co Ltd 含リンイソプレノイド誘導体
EP0541037A3 (en) * 1991-11-06 1997-02-26 Takeda Chemical Industries Ltd Squalene synthetase inhibitory composition and use thereof
JPH06172372A (ja) * 1991-11-06 1994-06-21 Takeda Chem Ind Ltd スクアレン合成酵素阻害剤およびその用途
US5366965A (en) * 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
EP0688325A1 (de) * 1993-03-08 1995-12-27 Eisai Co., Ltd. Phosphonsaure derivate
US5510517A (en) 1993-08-25 1996-04-23 Merck & Co., Inc. Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
EP0705834A1 (de) 1994-07-27 1996-04-10 Ciba-Geigy Ag Azaaliphatisch Überbrückte Chinoxalin-2,3-dione
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US7645460B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
WO2006039721A2 (en) 2004-10-08 2006-04-13 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
US7781418B2 (en) 2006-12-14 2010-08-24 Isis Innovation Ltd. Composition for treating bone disorders
KR20110079813A (ko) 2008-09-22 2011-07-08 아이시스 이노베이션 리미티드 이미다조〔1,2-α〕피리디닐 비스포스포네이트
EP2344503B1 (de) 2008-09-22 2014-04-16 Isis Innovation Ltd 5-azaindol-bisphosphonate
WO2010033980A2 (en) 2008-09-22 2010-03-25 Isis Innovation Ltd. 4-azaindole bisphosphonates
IN2012DN03448A (de) 2009-10-26 2015-10-23 Warner Chilcott Co Llc

Also Published As

Publication number Publication date
IL219235A0 (en) 2012-06-28
IL219235A (en) 2017-01-31
US8314081B2 (en) 2012-11-20
US8710215B2 (en) 2014-04-29
CN102630227A (zh) 2012-08-08
WO2011056589A1 (en) 2011-05-12
MX2012004769A (es) 2012-08-08
CA2778015A1 (en) 2011-05-12
EP2493905B1 (de) 2016-11-30
US20140194389A1 (en) 2014-07-10
EP2493905A1 (de) 2012-09-05
CA2778015C (en) 2016-08-02
SG10201406846XA (en) 2014-12-30
US8822435B2 (en) 2014-09-02
JP2013508459A (ja) 2013-03-07
CN102630227B (zh) 2016-03-23
US20110098251A1 (en) 2011-04-28
JP5850842B2 (ja) 2016-02-03
US20130035482A1 (en) 2013-02-07

Similar Documents

Publication Publication Date Title
IN2014DN09805A (de)
TN2012000126A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
IN2012DN02177A (de)
IN2012DN00754A (de)
WO2009135190A3 (en) Therapeutic calcium phosphate particles and methods of making and using same
EA201290482A1 (ru) Стабильные составы для лиофилизации терапевтических частиц
IN2014DN09804A (de)
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
MX2011007930A (es) Conjugados de insulina cristalina.
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
MY155564A (en) Arginine salts and their uses for the treatment of illnesses in the oral cavity
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MY156302A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2012001660A (es) Formulaciones que contienen linaclotida para adminstracion oral.
IN2012DN03448A (de)
MX337849B (es) Composiciones y metodos para inhibicion de la via jak.
WO2011023367A3 (en) Bisphosphonate-prodrugs
BR112012026098A2 (pt) métodos e composições para melhorar a osseointegração de implante.
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
PH12015500111A1 (en) Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2009011577A (es) Composiciones y metodos para distribucion de domperidona a traves de la mucosa.
WO2011147034A8 (en) Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof